Active surveillance provides an important alternative to immediate treatment for early-stage, low-risk prostate cancers. For men with a relatively short life expectancy, watchful waiting is recommended.
Adverse events observed in sarcoma survivors highlights the increased need for new, safe treatments, as complications may not be seen until years after the completion of therapy.
The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.
The development of ALK inhibitors for non-small cell lung cancer is rapidly progressing, yet acquired treatment resistance remains a key issue for a majority of patients.
Though imperiled by efforts to repeal the Affordable Care Act, the federal Open Payments transparency program is helping to expose industry payments to physicians.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA 1/2 Status in Triple-negative Breast Cancer May Affect Responsiveness to Carboplatin
- Overcoming Resistance to ALK Inhibition in Lung Cancer
- Low-fat Diet and Breast Cancer
- Industry Payments to Physicians: Confronting Conflicts of Interest
- The Adverse Effects of Sarcoma Treatment in Cancer Survivors
- Gilteritinib Granted Orphan Drug Status for Acute Myeloid Leukemia
- Does Alcohol Raise the Risk of Bladder Cancer?
- Nivolumab Provides Durable Response in dMMR/MSI-H Colorectal Cancer
- Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer
- Some Patients With Terminal Cancer Receive Unnecessary Aggressive Treatment